Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01489189 · ClinicalTrials.gov registry record · Phase 3
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
A Phase 3 study, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 305
- Enrollment target
NCT01489189 is a Phase 3 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 305 participants.
The verdict
NCT01489189, a Phase 3 study, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 305 participants
- Enrollment target
Study Summary
The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard prompt PRP therapy. Secondary objectives include: * Comparing other visual function outcomes (including Humphrey visual field testing and study participant self-reports of visual function) in eyes receiving anti-VEGF with deferred PRP with those in eyes receiving prompt PRP. * Determining percent of eyes not requiring PRP when anti-VEGF is given in the absence of prompt PRP. * Comparing safety outcomes between treatment groups. * Comparing associated treatment and follow-up exam costs between treatment groups.
Interventions
- OTHER Prompt Panretinal Photocoagulation
- DRUG 0.5-mg Ranibizumab
- OTHER Deferred panretinal photocoagulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2012-03 |
| Est. Completion | 2018-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01489189
The ClinicalTrials.gov registry entry for NCT01489189 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prompt Panretinal Photocoagulation is the first listed.
NCT01489189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01489189 about?
NCT01489189 is a clinical study titled "Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy". The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes ...
What is the current status of trial NCT01489189?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 305 participants. The study started on 2012-03. Estimated completion is 2018-02-05.
What interventions are being tested in trial NCT01489189?
The interventions under investigation include: Prompt Panretinal Photocoagulation (OTHER), 0.5-mg Ranibizumab (DRUG), Deferred panretinal photocoagulation (OTHER).
Who is sponsoring clinical trial NCT01489189?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.